低吸资金买到溢价！溢价率升超0.6%，数亿巨资密集加仓港股通创新药ETF（520880）布局后市

Core Viewpoint - Significant capital is being invested in innovative drugs, with the Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing strong buying momentum and a premium trading rate exceeding 0.6% as of November 4 [1] Group 1: Market Activity - The Hong Kong Stock Connect Innovative Drug ETF (520880) has attracted nearly 220 million yuan in the last 10 days as of November 3, indicating robust investor interest [1] - The ETF manager, Feng Chen Cheng, suggests that the innovative drug market may soon see a resurgence due to improved geopolitical conditions between China and the U.S. following a recent meeting between leaders [1] - The recent quarterly reports from companies like Innovent Biologics and Hengrui Medicine have confirmed strong performance in the innovative drug sector, further boosting investor confidence [1] Group 2: Policy and Industry Outlook - The policy environment remains supportive of innovative drugs, with recent information from medical insurance negotiations indicating continued favorable conditions for original innovations [1] - Huafu Securities notes that the focus of the innovative drug market is shifting from broad valuation recovery to the fundamental performance of companies, emphasizing the importance of clinical data, commercialization capabilities, and international expansion potential [1] Group 3: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which exclusively includes innovative drug R&D companies and has a high concentration in large-cap leaders [2] - As of September 30, the index has seen a year-to-date increase of 108.14%, outperforming other innovative drug indices [2] - The ETF has reached a record fund size of over 2 billion yuan as of November 3, with an average daily trading volume of 474 million yuan, making it the largest and most liquid ETF in its category [2]